Loading...
Market
Predominant outcome for Bluebird Bio therapy patients by end of 2025?
2
Resolution / Starting Odds
Improved survival rates • 25%
Increased cancer rates • 25%
Stable condition • 25%
Other • 25%
Published study results or official announcements
Story
Bluebird Bio Gene Therapy Benefits Marred by 7 Children Developing MDS and AML
Oct 9, 2024, 09:25 PM
Bluebird Bio's gene therapy for cerebral adrenoleukodystrophy has shown long-term benefits for patients, with most of the 32 treated patients remaining free of major disability after a median of 6 years. However, concerning findings have emerged, with seven children developing blood cancer, specifically myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), 14 to 92 months post-treatment. These cases were previously disclosed to investigators and the FDA, leading to an update in the Skysona label in April. The study, published in the New England Journal of Medicine (NEJM), highlights the difficult choices faced by families of affected children. The research involved lead and senior authors from Dana-Farber.
View original story
Similar markets
Yes • 50%
No • 50%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Complete remission • 25%
Partial remission • 25%
No change • 25%
Worsening condition • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
Less than $500,000 • 25%
$500,000 - $1,000,000 • 25%
$1,000,000 - $1,500,000 • 25%
More than $1,500,000 • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Universal gene therapy • 33%
Mutation-specific gene therapy • 33%
No approval • 34%